Efficacy and safety of teclistamab (tec), a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM) after exposure to other BCMA-targeted agents.

被引：0

作者：

Touzeau, Cyrille

Krishnan, Amrita Y.

Moreau, Philippe

Perrot, Aurore

Usmani, Saad Zafar

Manier, Salomon

Cavo, Michele

Martinez-Chamorro, Carmen

Nooka, Ajay K.

Martin, Thomas G.

Karlin, Lionel

Leleu, Xavier

Bahlis, Nizar J.

Besemer, Britta

Pei, Lixia

Verona, Raluca

Girgis, Suzette

Uhlar, Clarissa

Kobos, Rachel

Garfall, Alfred L.

机构：

[1] Univ Hosp Hotel Dieu, Nantes, France

[2] City Hope Comprehens Canc Ctr, Duarte, CA USA

[3] Univ Toulouse, Ctr Hosp, Serv Hematol, Toulouse, France

[4] Levine Canc Inst Atrium Hlth, Charlotte, NC USA

[5] Univ Lille, Lille, France

[6] Univ Bologna, IRCSS Aziena Ospedaliero Univ Bologna, Sch Med, Bologna, Italy

[7] Univ Hosp Quironsalud, Pozuelo Alarc, Madrid, Spain

[8] Emory Univ Hosp, Winship Canc Inst, Atlanta, GA USA

[9] Univ Calif San Francisco, San Francisco, CA USA

[10] Ctr Hosp Lyon Sud, Serv Hematol Clin, Pierre Benite, France

[11] Ctr Hosp Univ Poitiers, Poitiers, France

[12] Univ Calgary, Arnie Charbonneau Canc Inst, Calgary, AB, Canada

[13] Univ Tubingen Hosp, Tubingen, Germany

[14] Janssen Res & Dev, Raritan, NJ USA

[15] Janssen Res & Dev, Spring House, PA USA

[16] Univ Pennsylvania, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8013

引用

页数：1